Elvevåg B, Goldberg TE (2000) Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 14(1):1–21

Article  PubMed  Google Scholar 

Sharma T, Antonova L (2003) Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 26(1):25–40. https://doi.org/10.1016/s0193-953x(02)00084-9

Article  PubMed  Google Scholar 

García RR, Aliste F, Soto G (2018) Social cognition in schizophrenia: cognitive and neurobiological aspects. Rev Colomb Psiquiatr (Engl Ed) 47(3):170–176. https://doi.org/10.1016/j.rcp.2017.03.004

Article  PubMed  Google Scholar 

Sampedro A, Peña J, Ibarretxe-Bilbao N, Sánchez P, Iriarte-Yoller N, Pavón C, Hervella I, Tous-Espelosin M, Ojeda N (2020) Neurocognitive, social cognitive, and clinical predictors of creativity in schizophrenia. J Psychiatr Res 129:206–213. https://doi.org/10.1016/j.jpsychires.2020.06.019

Article  PubMed  Google Scholar 

Bang M, Kim KR, Song YY, Baek S, Lee E, An SK (2015) Neurocognitive impairments in individuals at ultra-high risk for psychosis: Who will really convert? Aust N Z J Psychiatry 49(5):462–470. https://doi.org/10.1177/0004867414561527

Article  PubMed  Google Scholar 

Bora E, Binnur Akdede B, Alptekin K (2017) Neurocognitive impairment in deficit and non-deficit schizophrenia: a meta-analysis. Psychol Med 47(14):2401–2413. https://doi.org/10.1017/s0033291717000952

Article  CAS  PubMed  Google Scholar 

Mohn C, Olsson AK, Johansson M, Moradi H, Helldin L (2021) Marginal relationship between affective dispositions and neurocognitive function in patients with schizophrenia spectrum disorders. Nord J Psychiatry 75(5):344–350. https://doi.org/10.1080/08039488.2020.1862294

Article  PubMed  Google Scholar 

Leifker FR, Bowie CR, Harvey PD (2009) Determinants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptoms. Schizophr Res 115(1):82–87. https://doi.org/10.1016/j.schres.2009.09.004

Article  PubMed  Google Scholar 

Peuskens J, Demily C, Thibaut F (2005) Treatment of cognitive dysfunction in schizophrenia. Clin Ther 27(Suppl A):S25-37. https://doi.org/10.1016/j.clinthera.2005.07.015

Article  CAS  PubMed  Google Scholar 

Carbon M, Correll CU (2014) Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr 1(19 Suppl):38–52. https://doi.org/10.1017/s1092852914000601. (quiz 35-37, 53)

Article  Google Scholar 

Zhu MH, Liu ZJ, Hu QY, Yang JY, Jin Y, Zhu N, Huang Y, Shi DH, Liu MJ, Tan HY, Zhao L, Lv QY, Yi ZH, Wu FC, Li ZZ (2022) Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. Mil Med Res 9(1):59. https://doi.org/10.1186/s40779-022-00420-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan RCK, Geng FL, Lui SSY, Wang Y, Ho KKY, Hung KSY, Gur RE, Gur RC, Cheung EFC (2015) Course of neurological soft signs in first-episode schizophrenia: relationship with negative symptoms and cognitive performances. Sci Rep 5:11053. https://doi.org/10.1038/srep11053

Article  PubMed  PubMed Central  Google Scholar 

Chang WC, Tang JY, Hui CL, Wong GH, Chan SK, Lee EH, Chen EY (2013) The relationship of early premorbid adjustment with negative symptoms and cognitive functions in first-episode schizophrenia: a prospective three-year follow-up study. Psychiatry Res 209(3):353–360. https://doi.org/10.1016/j.psychres.2013.02.014

Article  PubMed  Google Scholar 

Rek-Owodziń K, Tyburski E, Plichta P, Waszczuk K, Bielecki M, Wietrzyński K, Podwalski P, Rudkowski K, Michalczyk A, Grąźlewski T, Sagan L, Kucharska-Mazur J, Samochowiec J, Mak M (2022) The relationship between cognitive functions and psychopathological symptoms in first episode psychosis and chronic schizophrenia. J Clin Med. https://doi.org/10.3390/jcm11092619

Article  PubMed  PubMed Central  Google Scholar 

Brébion G, Bressan RA, Ohlsen RI, David AS (2013) A model of memory impairment in schizophrenia: cognitive and clinical factors associated with memory efficiency and memory errors. Schizophr Res 151(1–3):70–77. https://doi.org/10.1016/j.schres.2013.09.009

Article  PubMed  Google Scholar 

Hartmann-Riemer MN, Hager OM, Kirschner M, Bischof M, Kluge A, Seifritz E, Kaiser S (2015) The association of neurocognitive impairment with diminished expression and apathy in schizophrenia. Schizophr Res 169(1–3):427–432. https://doi.org/10.1016/j.schres.2015.10.032

Article  PubMed  Google Scholar 

Liemburg E, Castelein S, Stewart R, van der Gaag M, Aleman A, Knegtering H (2013) Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. J Psychiatr Res 47(6):718–725. https://doi.org/10.1016/j.jpsychires.2013.01.024

Article  PubMed  Google Scholar 

Wu Q, Wang X, Wang Y, Long YJ, Zhao JP, Wu RR (2021) Developments in biological mechanisms and treatments for negative symptoms and cognitive dysfunction of schizophrenia. Neurosci Bull 37(11):1609–1624. https://doi.org/10.1007/s12264-021-00740-6

Article  PubMed  PubMed Central  Google Scholar 

Lim J, Lee SA, Lam M, Rapisarda A, Kraus M, Keefe RS, Lee J (2016) The relationship between negative symptom subdomains and cognition. Psychol Med 46(10):2169–2177. https://doi.org/10.1017/s0033291716000726

Article  CAS  PubMed  Google Scholar 

Bora E (2019) Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis. Psychol Med 49(12):1971–1979. https://doi.org/10.1017/s0033291719001685

Article  PubMed  Google Scholar 

Çakici N, Sutterland AL, Penninx B, Dalm VA, de Haan L, van Beveren NJM (2020) Altered peripheral blood compounds in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis. Brain Behav Immun 88:547–558. https://doi.org/10.1016/j.bbi.2020.04.039

Article  CAS  PubMed  Google Scholar 

Goldsmith DR, Rapaport MH, Miller BJ (2016) A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 21(12):1696–1709. https://doi.org/10.1038/mp.2016.3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Halstead S, Siskind D, Amft M, Wagner E, Yakimov V, Shih-Jung Liu Z, Walder K, Warren N (2023) Alteration patterns of peripheral concentrations of cytokines and associated inflammatory proteins in acute and chronic stages of schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry 10(4):260–271. https://doi.org/10.1016/s2215-0366(23)00025-1

Article  PubMed  Google Scholar 

Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB (2015) Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2(3):258–270. https://doi.org/10.1016/s2215-0366(14)00122-9

Article  PubMed  PubMed Central  Google Scholar 

Na KS, Jung HY, Kim YK (2014) The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 48:277–286. https://doi.org/10.1016/j.pnpbp.2012.10.022

Article  CAS  PubMed  Google Scholar 

Campana M, Strauß J, Münz S, Oviedo-Salcedo T, Fernando P, Eichhorn P, Falkai P, Hasan A, Wagner E (2022) Cerebrospinal fluid pathologies in schizophrenia-spectrum disorder-a retrospective chart review. Schizophr Bull 48(1):47–55. https://doi.org/10.1093/schbul/sbab105

Article  PubMed  Google Scholar 

Jacomb I, Stanton C, Vasudevan R, Powell H, O’Donnell M, Lenroot R, Bruggemann J, Balzan R, Galletly C, Liu D, Weickert CS, Weickert TW (2018) C-reactive protein: higher during acute psychotic episodes and related to cortical thickness in schizophrenia and healthy controls. Front Immunol 9:2230. https://doi.org/10.3389/fimmu.2018.02230

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ji E, Boerrigter D, Cai HQ, Lloyd D, Bruggemann J, O’Donnell M, Galletly C, Lloyd A, Liu D, Lenroot R, Weickert TW, Shannon Weickert C (2022) Peripheral complement is increased in schizophrenia and inversely related to cortical thickness. Brain Behav Immun 101:423–434. https://doi.org/10.1016/j.bbi.2021.11.014

Article